New Chinese weight-loss jab could rival Wegovy and Mounjaro
Chinese jab could rival Wegovy and Mounjaro

Chinese-developed ribupatide helped trial participants lose up to 17.7% of their body weight in under a year, according to a study that suggests the jab could rival popular weight-loss drugs such as Wegovy.

The drug is still being trialled in the UK, but early results show it can help some people shed nearly a fifth of their body weight in less than 11 months. The findings come months after patients in the UK were recruited for phase three trials of the drug.

Trial Results Show Significant Weight Loss

During the study, people on the highest dose of ribupatide lost 17.7% of their body weight in just 11 months. By comparison, Wegovy, which contains the active ingredient semaglutide, generally helps people shed 18.7% over 16-and-a-half months, while Mounjaro, made with tirzepatide, sees users lose around 22.5% over the same period.

Like Mounjaro, ribupatide works by mimicking two hormones that help control appetite and blood sugar.

Study Details and Additional Benefits

The study, conducted by researchers at Shanghai's Fudan University, involved 567 overweight adults with an average age of 34. Of these, 424 were randomly selected to receive weekly ribupatide injections at doses of 2mg, 4mg or 6mg, while the remaining 143 received a placebo.

After 48 weeks, patients given the lowest dose lost an average of 10.7% of their starting weight. Participants on the middle dose shed 16.4%, while those taking the highest amount lost 17.7%. Patients given the placebo injection lost just 1.4%.

Some participants lost even more, with 13.6% of the 142 patients on 2mg losing at least a fifth of their body weight, rising to 37.1% of the 141 taking 4mg and 44.4% of the 141 taking 6mg.

Beyond Weight Loss

The jab also appeared to offer benefits beyond weight loss, with researchers finding improvements in measurements such as blood pressure, blood sugar control and cholesterol. Blood pressure fell by around seven to nine points more than among patients given the placebo.

Triglycerides, a type of fat found in the blood that can cause serious health problems when levels become too high, fell by around 29 to 37% more than with the dummy jab. Cholesterol levels also reduced by 6% at 2mg, 9% at 4mg and 8% at 6mg.

Weight loss typically slows over time because the body burns fewer calories as it gets smaller. Like other weight-loss medications, ribupatide's most common side effects are stomach and digestive problems.

Some 1.6 million adults in England, Wales, and Scotland used weight-loss injections between early 2024 and 2025, according to research from University College London.